I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on <u>December 1, 2003</u>

flew & Vadwi

Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE STATEMENT

Examining Group 1644

Patent Application

Docket No. UF-T397XC1

Serial No 09/787,144

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Maher M. Haddad

Art Unit

1644

Applicants

Nasser Chegini, James Burns, Michael P. Diamond, Lena E. Holmdahl

Serial No.

09/787,144

Filed

March 13, 2001

For

Prevention of Adhesions

RECEIVED

DEC 0 8 2003

TECH CENTER 1600/2900

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

> INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §\$1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted.

Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of references cited therein

J:\UF\T397XC1\PTO\IDS.pto.doc/DNB/mv

ECCE O 311

DEC 0 3 2003

PTC/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

CIBADEMA Complete if Known Substitute for form 1449A/PTO **Application Number** 09/787,144 INFORMATION DISCLOSURE **Filing Date** March 13, 2001 STATEMENT BY APPLICANT First Named Inventor Nasser Chegini (use as many sheets as necessary) **Art Unit** 1644 **Examiner Name** Maher M. Haddad Sheet of **Attorney Docket Number** 2 UF-T397XC1

			U.S. PATENT DO	OCUMENTS	-	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-2003/0176332 A1	09-18-2003	Olmarker	All	
	U2	US-2003/0096755 A1	05-22-2003	Brunner et al.	All	
	U3	US-2001/0034327 A1	10-25-2001	Brunner et al.	All	
	U4	US-			DEOE!	/ /
	U5	US-			RECEIV	
	U6	US-			DEC.	
	U7	US-			DEC 0 8 20)03
	U8	US-			TENLARITE	
	U9	US-			TECH CENTER 160)0/2

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document	D. L.V 4' D - 4 -	Name of Datastance	Pages, Columns, Lines,	
Examiner Initials*	Cite No. 1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DEC 0 3 2003

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons

required to

of

2

Substitute for form 1449B/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/787,144
Filing Date	March 13, 2001
First Named Inventor	Nasser Chegini
Group Art Unit	1644
Examiner Name	Maher M. Haddad
Attorney Docket Number	UF-T397XC1

Complete if Known

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ALEXANDER, C.M. and WERB, Z. "Targeted Disruption of the Tissue Inhibitor of Metalloproteinases Gene Increases the Invasive Behavior of Primitive Mesenchymal Cells Derived from Embryonic Stem Cells In Vitro" <i>J. Cell Biol.</i> , 1992, 118:727-739.	
	R2	CHEGINI, N. et al. "Comparative Analysis of Matrix Metalloproteanase (MMP-1), Tissue Inhibitor of MMP (TIMP-1) and MMP-1/TIMP-1 Complex Expression in Intraperitoneal Environment and Their Relation to Adhesion Development" Fertility and Sterility, mailed to subscribers September 1998, 70(No. 3, Suppl. 1):S26-S27, abstract.	
	R3	FOROUGH, R. et al. "Generating Antibodies Against Secreted Proteins Using Vascular Smooth Muscle Cells Transduced with Replication-Defective Retrovirus" <i>BioTechniques</i> , 1996, 20:694-701.	
	R4	KHOKHA, R. et al. "Antisense RNA—Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells" Science, 1989, 243(4893):947-950.	
	R5		
	R6	RECEIVED	
,	R7	DEC 0 8 2003	
	R8	TECH CENTER 1600/29	00
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner	Date	
Signature	Considered	1 1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.